History of ectonucleotidases and their role in purinergic signaling.


Journal

Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032

Informations de publication

Date de publication:
05 2021
Historique:
received: 29 09 2020
revised: 03 11 2020
accepted: 03 11 2020
pubmed: 9 11 2020
medline: 15 9 2021
entrez: 8 11 2020
Statut: ppublish

Résumé

Ectonucleotidases are key for purinergic signaling. They control the duration of activity of purinergic receptor agonists. At the same time, they produce hydrolysis products as additional ligands of purinergic receptors. Due to the considerable diversity of enzymes, purinergic receptor ligands and purinergic receptors, deciphering the impact of extracellular purinergic receptor control has become a challenge. The first group of enzymes described were the alkaline phosphatases - at the time not as nucleotide-metabolizing but as nonspecific phosphatases. Enzymes now referred to as nucleoside triphosphate diphosphohydrolases and ecto-5'-nucleotidase were the first and only nucleotide-specific ectonucleotidases identified. And they were the first group of enzymes related to purinergic signaling. Additional research brought to light a surprising number of ectoenzymes with broad substrate specificity, which can also hydrolyze nucleotides. This short overview traces the development of the field and briefly highlights important results and benefits for therapies of human diseases achieved within nearly a century of investigations.

Identifiants

pubmed: 33161020
pii: S0006-2952(20)30558-X
doi: 10.1016/j.bcp.2020.114322
pii:
doi:

Substances chimiques

Purinergic Agonists 0
Purinergic Antagonists 0
Receptors, Purinergic 0
Adenosine Triphosphate 8L70Q75FXE
5'-Nucleotidase EC 3.1.3.5

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

114322

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Herbert Zimmermann (H)

Goethe University, Institute of Cell Biology and Neuroscience, Max-von-Laue-Str. 13, 60438 Frankfurt am Main, Germany. Electronic address: h.zimmermann@bio.uni-frankfurt.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH